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RESEARCH ARTICLE
Rodent heart failure models do not reflect the
human circulating microRNA signature in
heart failure
Eline L. Vegter1, Ekaterina S. Ovchinnikova1,2, Herman H. W. Sillje´1, Laura M. G. Meems1,
Atze van der Pol1, A. Rogier van der Velde1, Eugene Berezikov2, Adriaan A. Voors1, Rudolf
A. de Boer1, Peter van der Meer1*
1 Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The





We recently identified a set of plasma microRNAs (miRNAs) that are downregulated in
patients with heart failure in comparison with control subjects. To better understand their
meaning and function, we sought to validate these circulating miRNAs in 3 different well-
established rat and mouse heart failure models, and correlated the miRNAs to parameters
of cardiac function.
Methods
The previously identified let-7i-5p, miR-16-5p, miR-18a-5p, miR-26b-5p, miR-27a-3p, miR-
30e-5p, miR-199a-3p, miR-223-3p, miR-423-3p, miR-423-5p and miR-652-3p were mea-
sured by means of quantitative real time polymerase chain reaction (qRT-PCR) in plasma
samples of 8 homozygous TGR(mREN2)27 (Ren2) transgenic rats and 8 (control) Sprague-
Dawley rats, 6 mice with angiotensin II-induced heart failure (AngII) and 6 control mice, and
8 mice with ischemic heart failure and 6 controls. Circulating miRNA levels were compared
between the heart failure animals and healthy controls.
Results
Ren2 rats, AngII mice and mice with ischemic heart failure showed clear signs of heart fail-
ure, exemplified by increased left ventricular and lung weights, elevated end-diastolic left
ventricular pressures, increased expression of cardiac stress markers and reduced left ven-
tricular ejection fraction. All miRNAs were detectable in plasma from rats and mice. No sig-
nificant differences were observed between the circulating miRNAs in heart failure animals
when compared to the healthy controls (all P>0.05) and no robust associations with cardiac
function could be found.
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Conclusions
The previous observation that miRNAs circulate in lower levels in human patients with heart
failure could not be validated in well-established rat and mouse heart failure models. These
results question the translation of data on human circulating miRNA levels to experimental
models, and vice versa the validity of experimental miRNA data for human heart failure.
Introduction
MicroRNAs (miRNAs) regulate gene expression at the posttranscriptional level by degrading
or inhibiting target messenger RNAs (mRNAs). To date, several miRNAs have been described
having key roles in cardiac development and cardiovascular disease [1]. Furthermore, several
miRNAs have been implicated in the etiology and progression of heart failure [2].
Since the discovery that miRNAs circulate in blood, the search began for new heart failure
biomarkers aiding in the diagnosis, prognosis and evaluation of therapy. Previously, we identi-
fied a panel of heart failure related circulating miRNAs [3]. These miRNAs were all down-
regulated in heart failure patients compared to healthy subjects or to patients with respiratory
distress due to chronic obstructive pulmonary disease. Further, these miRNAs showed the
lowest levels in patients with acute heart failure and a gradual increase towards more stable
chronic heart failure and healthy controls, and could be linked to several pathways implicated
in the pathophysiology of heart failure [3,4]. These results however contradict the findings of
several animal studies of heart failure that report most candidate miRNAs in myocardial tissue
to be upregulated, rather than downregulated [5–7]. There are very few data on circulating
miRNAs in animal models of heart failure, and both up- and downregulated levels of the dif-
ferentially expressed miRNAs in the bloodstream have been reported [8,9].
So, while an increasing number of studies identified ever new candidate biomarkers in
heart failure patients, few groups conducted experimental follow-up studies in order to gain
mechanistic insight into the biology of circulating miRNAs. Animal heart failure models could
be useful tools for this purpose and therefore we aimed to investigate an established set of
human heart failure related miRNAs in 3 rodent heart failure models.
Material and methods
Animals
Animal experiments were performed in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by the Animal Ethical
Committee of the University of Groningen (permit numbers DEC6954A, DEC6661A and
DEC1583-2). Both rats and mice were housed in a 12:12 hour day:night cycle, were monitored
regularly and had ad libitum access to food and water.
Ren2 transgenic rats. Eight homozygous TGR(mREN2)27 (Ren2) male transgenic rats
(Max Delbru¨ck Center for Molecular Medicine, Berlin-Buch, Germany) were studied. Homo-
zygous Ren2 rats overexpress the mouse renin-2 gene (ren-2d) and develop severe hyperten-
sion and a phenotype of fast forward heart failure within 12–16 weeks, as previously described
[10]. Eight age-matched, male Sprague-Dawley (SD) rats were used as control animals (Harlan,
The Netherlands).
Angiotensin II infused mice. Six 10-week-old male C57Bl/6J mice (Harlan, The Nether-
lands) underwent subcutaneous administration of angiotensin II (AngII) 2.5 μg/kg per day via
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osmotic minipumps (Alzet, Palo Alto, CA, USA, model 2004) for 14 days, as previously
reported [11]. Six male C57Bl/6J littermates that received subcutaneous saline 0.9% for 14 days
served as control group.
Ischemic heart failure mice. A total of 8 mice (age 14–16 weeks) underwent permanent
ligation of the left coronary artery (LAD) to induce myocardial infarction. Six control mice
also underwent surgery but without ligation of the LAD. MRI was performed 4 weeks after the
procedure and subsequently hemodynamic measurements were performed. At time of sacri-
fice, organs were removed and weighed, and blood samples were collected.
Cardiac magnetic resonance imaging (MRI)
Cardiac MRI measurements have been previously described in more detail [12]. After anesthe-
sia with 2% isoflurane, mice were placed in a vertical 9.4-T, 89-mm bore size magnet equipped
with 1500 mT/m gradients and connected to an advanced 400 MR system (Bruker Biospin)
using a quadrature-driven birdcage coil with an inner diameter of 3 cm. With the ECG Trigger
Unit (RAPID biomedical GmBH), respiration and heart rate were registered. Respiration rate
was kept between 20–60 breaths per minute and heart rate between 400–600 beats per minute.
Cine MR acquisition and reconstruction was performed with ParaVison 4.0 and IntraGate
software (Bruker Biospin GmH). For mice with ischemic heart failure, 8–9 slices were needed
for cardiac cine MR images and 7 for control animals. The software QMass (version MR 6.1.5,
Medis Medical Imaging Systems) was used to obtain the left ventricular (LV) end-diastolic vol-
ume (LVEDV), LV end-systolic volume (LVESV) and LV ejection fraction (LVEF).
Invasive hemodynamic measurements
Aortic and LV catheterization was performed in all animals as described before [13]. Briefly,
after anesthesia with 2% isoflurane an indwelling micromanometer-tipped pressure catheter
(0.8 F for AngII and control mice, 1.2 F for ischemic heart failure and control mice and 1.4 F
for rats; Millar Instruments, Houston, TX, USA) was inserted into the right carotid artery and
advanced into the LV to record intercardiac pressures. Heart rate, aortic pressures, LV end-
systolic pressures (LVESP), end-diastolic pressures (LVEDP), first derivative of force (dP/
dtmax) and relaxation constant Tau were measured. dP/dtmax values were corrected for peak
systolic pressure, as previously reported [10]. Second, after 3 minutes of stabilization, blood
pressure measurements were performed in the aortic arch.
Plasma processing
After the hemodynamic measurements, blood was drawn via cardiac puncture and collected
in EDTA tubes. Samples were centrifuged (3000 rpm) for 15 minutes, at 4˚ Celsius. Plasma
was directly stored and frozen in -80˚ Celsius.
MicroRNA measurements in plasma. The miRCURY RNA isolation kit for bodyfluids
from Exiqon (Vedbaek, Denmark) was used to isolate RNA from plasma samples of 16 rats
and 26 mice. The reversed transcription reactions were performed using the Universal cDNA
Synthesis kit (Exiqon). Using a customized Exiqon miRNA PCR panel, the levels of the follow-
ing circulating miRNAs -previously associated with heart failure-[3] were measured in 50 μl of
plasma using a customized Exiqon miRNA PCR panel suitable for rodents; let-7i-5p, miR-16-
5p, miR-18a-5p, miR-26b-5p, miR-27a-3p, miR-30e-5p, miR-199a-3p, miR-223-3p, miR-423-
3p, miR-423-5p and miR-652-3p. For the miRNA measurements in the ischemic heart failure
model we added 2 cardiac-specific miRNAs (miR-208a-3p and miR-499-5p) to our selection.
Polymerase chain reactions were conducted with the LightCycler1 480 (Roche Applied Sci-
ence, Rotkreuz, Switzerland) with cycle settings as recommended by Exiqon. With use of
Circulating microRNAs in rodent heart failure models
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synthetic RNA templates we controlled for isolation yield, cDNA synthesis and PCR efficiency.
Out of a panel of potential reference miRNAs, the miRNAs miR-30a-5p and cel-miR-39-3p for
plasma and miR-93-5p for tissue were selected as best performing by GeNorm and NormFin-
der (GenEx Professional software, MultiD Analyses, Sweden). Detailed information including
quality control and normalization of the miRNA measurements is provided in S1 Methods).
Expression levels of the measured miRNAs were normalized against the selected reference
genes. The delta Ct method was performed to obtain the relative miRNA expression levels
using the GenEx Professional software.
Tissue procurement
After hemodynamic measurements and blood collection, organs were rapidly excised and
weighed. The heart was dissected in atria, LV and right ventricle (RV). The LV myocardial tis-
sue was snap frozen in liquid nitrogen and stored at -80˚ Celsius and used for RNA analyses.
Tissue used for miRNA analyses were frozen and powdered before RNA isolation.
RNA isolation for microRNA measurements in tissue. Total RNA was isolated using
TRIzol (Invitrogen) according to manufacturer’s instructions. RNA quality and quantity was
measured by NanoDrop spectrophotometer (ND-1000, Nanodrop Technologies). The same
amount of total RNA (500 μg) per sample was used for the cDNA synthesis with miRCURY
LNA™ Universal RT cDNA Synthesis Kit (Exiqon).
Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) expression mea-
surements. To assess markers of cardiac wall stress and remodeling, we measured both ANP
and BNP in the LV of rats, and ANP in the LV of Ang II mice and controls. Total RNA was
extracted from tissue using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and 0.5 μg total
RNA was reverse transcribed to cDNA using the RNeasy Mini kit (Qiagen Inc, Valencia, CA,
USA). qRT-PCR was performed using C1000 Thermal Cycler CFX384 Real-Time PCR Detec-
tion System (Bio-Rad Laboratories, Veenendaal, The Netherlands). After quantification of
mRNA levels (Bio-Rad CFX Manager 2.0), transcript measurements were normalized against
the invariant transcript 36B4. Primer sequences used for qRT-PCR analyses are listed in S1
Table.
Statistical analyses
GenEx Professional software (MultiD Analyses, Sweden) was used for processing the raw
miRNA expression data. Other statistical analyses were conducted with R: A Language and
Environment for Statistical Computing, version 3.2.0 (R Foundation for Statistical Computing,
Vienna, Austria). Results are presented as mean and standard deviation when normally dis-
tributed or median and interquartile range when values were non-normally distributed.
Student’s t-tests were performed to investigate differences between normally distributed con-
tinuous variables and Mann-Whitney U tests for non-normally distributed continuous vari-
ables. Correlation analyses were performed between circulating miRNA levels and parameters
of cardiac function. Pearson product moment correlation was performed when data was nor-
mally distributed, while Spearman correlation analyses were used for non-normally distrib-
uted data. Unless otherwise stated, P-values of0.05 were considered significant.
Results
Animal characteristics
Ren2 and control rats. Mean age at time of sacrificing was 14.4±1.0 weeks for Ren2 rats
and 15.0±0.9 weeks for SD controls. Ren2 and control animal characteristics at time of
Circulating microRNAs in rodent heart failure models
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sacrificing including hemodynamic parameters and biomarker expression levels are presented
in Table 1. Ren2 rats showed significantly increased LV and lung weights corrected for total
body weight. The mean LVEDP and systolic blood pressure were elevated in the Ren2 rats
compared to the SD control rats. In addition, LV contractility was reduced as reflected by
lower corrected dP/dtmax values, and the LV relaxation time constant Tau was significantly
increased, all suggestive of progressive heart failure development. Further, expression levels of
cardiac stress markers ANP and BNP were both significantly higher in the LV of Ren2
animals.
AngII and control mice. The AngII and control mice were sacrificed around 12 weeks of
age. Both LV and lung weights were significantly higher in the AngII mice compared to the
control mice, reflecting cardiac hypertrophy and lung congestion (Table 2). Further, similar to
the Ren2 rats, systolic blood pressure was significantly higher in AngII mice than control mice
and although not significant, a trend of an increased LVEDP and LV relaxation parameter Tau
was found in the AngII mice compared to their healthy littermates. Moreover, ANP levels
were significantly higher in the LV of AngII animals.
Ischemic heart failure mice. Table 3 presents the characteristics of mice 4 weeks after
induction of myocardial infarction and mice without permanent ligation of the coronary
artery. Induction of myocardial infarction resulted in large infarct sizes (33.8±10.6%) and
these mice developed clear signs of heart failure including lower blood pressure, an increased
LVEDP and increased LV weights. Furthermore, LV contractility was decreased (as reflected
by low dP/dtmax values) and LV relaxation impaired. Cardiac MRI showed significantly ele-
vated end-diastolic and end-systolic volumes in ischemic heart failure mice compared to con-
trol animals and a severely deteriorated LVEF.
Table 1. Baseline characteristics rats.




Body weight (g) 395.0±28.4 365.9±43.0 0.128
LV weight (mg) 955.9±107.4 1389.0±173.7 <0.001
LV/BW ratio (mg/g) 2.4±0.26 3.8±0.36 <0.001
Lung weight (mg) 992.4±106.9 1194.0±310.9 0.120




Heart rate (beats/min) 319.0±37.4 330.9±25.3 0.471
Systolic blood pressure (mmHg) 108.0±7.0 148.6±17.4 <0.001
LVEDP (mmHg) 9.0±2.3 21.9±4.2 <0.001
dP/dtmax 62.3±4.1 51.5±4.0 <0.001




ANP/36B4 0.04±0.04 1.45±0.51 <0.001
BNP/36B4 0.30±0.11 1.13±0.33 <0.001
Values are presented as mean with standard deviation. SD indicates Sprague-Dawley; LV, left ventricle;
BW, body weight; LVEDP, left ventricular end-diastolic pressure; ANP, atrial natriuretic peptide and BNP, B-
type natriuretic peptide. dP/dtmax represents the maximum rise in LV pressure in early systole corrected for
peak systolic pressure.
https://doi.org/10.1371/journal.pone.0177242.t001
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Expression levels of circulating miRNAs
Figs 1–3 present the circulating miRNA levels of the detectable miRNAs in the plasma of all 3
different rodent heart failure models. In the Ren2 rats and AngII mice, as well as the ischemic
Table 2. Baseline characteristics AngII mice and controls.




Body weight (g) 28.0±2.5 27.3±1.4 0.559
LV weight (mg) 105.0±13.0 136.0±13.1 0.002
LV/BW ratio (mg/g) 3.7±0.3 5.0±0.6 <0.001
Lung weight (mg) 164.8±14.0 199.5±28.6 0.024




Heart rate (beats/min) 529.4±53.6 527.8±68.3 0.967
Systolic blood pressure (mmHg) 101.5±6.0 123.8±15.2 0.030
LVEDP (mmHg) 9.0±4.3 14.0±8.1 0.322
dP/dtmax 57.6±9.1 64.9±5.8 0.161




ANP/36B4 0.35±0.07 1.70±0.73 0.006
Values are presented as mean with standard deviation. LV indicates left ventricle; BW, body weight; LVEDP,
left ventricular end-diastolic pressure and ANP, atrial natriuretic peptide. dP/dtmax represents the maximum
rise in LV pressure in early systole corrected for peak systolic pressure.
https://doi.org/10.1371/journal.pone.0177242.t002
Table 3. Baseline characteristics of mice with ischemic heart failure (IHF) and controls.
Variable Control IHF P-value
Animal characteristics 6 8
Body weight (g) 33.1±3.2 34.5±0.9 0.260
LV weight (mg) 127.7±12.1 152.9±18.4 0.013
LV/BW ratio (mg/g) 3.9±0.1 4.4±0.5 0.024
Hemodynamic parameters
Heart rate (beats/min) 475.5±61.4 512.8±65.2 0.300
Systolic blood pressure (mmHg) 106.1±8.4 96.5±6.5 0.002
LVEDP (mmHg) 10.2±2.7 16.4±6.1 0.040
dP/dtmax 74.6±10.0 63.3±7.6 0.033
Tau (ms) 7.4±0.8 10.8±2.6 0.010
MRI parameters
LVEDV (ml) 73.6±8.9 121±28.1 0.002
LVESV (ml) 37.9±7.9 101.8±33.9 <0.001
LVEF (%) 48.8±6.3 17.4±8.4 <0.001
Infarct size (%) - 33.8±10.6 -
Values are presented as mean with standard deviation. LV indicates left ventricle; BW, body weight; LVEDP,
left ventricular end-diastolic pressure; MRI, magnetic resonance imaging; LVEDV, left ventricular end-
diastolic volume; LVESV, left ventricular end-systolic volume and LVEF, left ventricular ejection fraction. dP/
dtmax represents the maximum rise in LV pressure in early systole corrected for peak systolic pressure.
https://doi.org/10.1371/journal.pone.0177242.t003
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heart failure mice we did not observe any significant differences in plasma miRNA expression
levels compared to control animals (all P>0.05, see S2–S4 Tables). Of the cardiac specific miR-
NAs, miR-208a-3p was not detectable in the plasma of ischemic heart failure mice and miR-
499-5p showed the lowest miRNA expression levels in plasma compared to the other miRNAs
(Fig 3 and S4 Table).
In general, the rank order of the expression levels of the measured miRNAs was comparable
in mice and rats, with the highest miRNA levels of miR-16-5p and miR-223-3p and the lowest
levels of miR-199a-3p, miR-652-3p, miR-423-3p and miR-26b-5p (S1–S3 Figs). The majority
is in concordance with the rank order of the previously reported miRNA levels in patients
with acute- and chronic heart failure and healthy controls [3].
Fig 1. Circulating microRNA expression levels in Ren2 rats and Sprague-Dawley controls (SD). MiRNA expression levels are presented as
normalized -Ct values with the median, interquartile range, minimum and maximum values. Differences between groups were not significant for all miRNAs
(P>0.05).
https://doi.org/10.1371/journal.pone.0177242.g001
Fig 2. Circulating microRNA expression levels in AngII mice and controls. MiRNA expression levels are presented as normalized -Ct values with the
median, interquartile range, minimum and maximum values. Differences between groups were not significant for all miRNAs (P>0.05).
https://doi.org/10.1371/journal.pone.0177242.g002
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Correlations of plasma miRNA levels to parameters of cardiac function. Potential rela-
tions between the levels of the circulating miRNAs and parameters of cardiac function (includ-
ing LVEDP, LVESP, LVEDV, LVESV, LVEF, dP/dtmax, Tau, ANP and BNP) were investigated
using correlation analyses. In rats we found one significant correlation between the normalized
-Ct values of miR-423-3p and the dP/dtmax values (R = -0.53, P-value = 0.036). In AngII mice
and controls, miR-26b-5p was significantly correlated to both LVESP (R = 0.66, P-value =
0.037) and dP/dtmax values (R = 0.66, P-value = 0.038) and in mice with ischemic heart failure
and controls we found miR-27a-3p to be borderline significantly correlated to LVEF (R =
-0.56, P-value = 0.049). However, the above findings did not reach significance after P-value
adjustment using Bonferroni correction for multiple testing.
Expression levels of miRNAs in tissue
To gain more insight in the miRNA expression in tissue, we additionally measured the miR-
NAs of interest in the LV and kidney of ischemic heart failure mice and controls. In addition
to the cardiac specific miR-208a-3p and miR-499-5p, we found that the expression of let-7i-5p,
miR-16-5p, miR-27a-3p, miR-199a-3p and miR-223-3p was significantly higher in the heart
compared to the kidney, independent of the presence of ischemic heart failure (S4 Fig and S5
Table). No differences in miRNA expression were found in kidneys of ischemic heart failure
mice compared to control animals (S6 Table) and only small differences were observed
between expression levels of miR-18a-5p, miR-30e-5p, miR-199a-3p and miR-223-3p in the
LV of mice with ischemic heart failure compared to controls (S7 Table), however not reaching
significance after Bonferroni correction for multiple testing.
Discussion
In cells, it is well-known that miRNAs exert a gene regulating function by targeting the comple-
mentary mRNA, which leads to either degradation or translational repression of the mRNA and
hence a disturbed protein production [14]. However, outside cells and in circulating blood the
function of miRNAs is largely unknown. The discovery of circulating miRNAs attracted strong
attention in several diseases, including heart failure, as it was hypothesized that the circulating
miRNAs may be used as a proxy for local production and may potentially be useful as biomark-
ers or guide for therapy. However, more recent data on circulating miRNAs do not corroborate
Fig 3. Circulating microRNA expression levels in ischemic heart failure mice and controls. MiRNA expression levels are presented as normalized -Ct
values with the median, interquartile range, minimum and maximum values. Differences between groups were not significant for all miRNAs (P>0.05).
https://doi.org/10.1371/journal.pone.0177242.g003
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the changes observed in cardiac tissue. We herein set out to validate the striking observation we
recently made that the most differentially expressed circulating miRNAs in human heart failure
are downregulated, by measuring this comprehensive set of circulating miRNAs in rats and
mice with heart failure. The main conclusions of this study are that 1) the selected miRNAs are
detectable in plasma of rats and mice, and that 2) levels of miRNAs do not differ between healthy
animals and animals with heart failure, nor correlate with parameters of cardiac function.
One possible reason for the lack of differentially expressed circulating miRNAs in the 3
heart failure models might be the fact that although the selected experimental animal models
are well-established and often used in heart failure studies, they might not accurately reflect
the human clinical diagnosis of heart failure. Transgenic Ren2 rats develop severe hyperten-
sion at an early age and as a consequence cardiac hypertrophy and heart failure [15]. AngII
infusion in mice also results in hypertension, hypertrophy and cardiac fibrosis [16]. The ani-
mals in both models develop heart failure due to pressure overload and an activated RAS sys-
tem, while in human heart failure, etiology is more diverse and ischemic etiology is often
predominant, as reflected in our ischemic heart failure mouse model. Despite these 3 diverse
rodent heart failure models, none of the models showed any differences in circulating miRNA
expression levels. However, these models could possibly reflect more accurately the chronic
heart failure state than acute heart failure, in which we previously found the most pronounced
downregulation of circulating miRNAs. Nevertheless, also in patients with more stable forms
of heart failure and chronic heart failure we consistently found lower levels of these circulating
miRNAs [3].
As these heart failure animal models only reflect the heart failure syndrome in its purest
form, other contributing factors important in human heart failure may not be well-represented
(or not extensively enough) to result in a differential miRNA response. It is conceivable that
our panel of miRNAs reflect other underlying mechanisms contributing to or coexisting with
heart failure. Although we do believe that the previously discovered signature of circulating
miRNAs in heart failure patients is strongly associated with the heart failure syndrome [3], it is
possible that these miRNAs reflect other, less obvious disease processes or comorbidities. For
example, previous work from our group showed a clear link between this panel of miRNAs
and atherosclerotic pathophysiological processes such as angiogenesis, endothelial dysfunction
and inflammation in heart failure patients [17]. Further, concomitant medication use in heart
failure patients such as diuretics, ACE inhibitors and beta-blockers are not taken into account
in the current heart failure animal models.
It seems unlikely that the lack of conservation between miRNA expression in humans com-
pared to rodents could have contributed to the discrepancy between the miRNA differences
found in human plasma and animals with heart failure. In general, miRNAs are well-conserved
between species [18] and also a recent study reported highly similar miRNA expression pat-
terns in different organs of rats and humans [19]. Indeed, the majority of miRNAs we previ-
ously identified in human plasma had similar sequences in both mice and rats, except for miR-
223-3p (similar between humans and mice, different in rats) and miR-106a-5p (not present in
rats and different in mice). However, the regulation of processes controlling the release and
uptake of miRNAs into and from the circulation during disease may be different in rodents
and humans.
To our knowledge, no other studies measured established circulating miRNAs in human
heart failure in heart failure rodent models. In human and rodent pulmonary hypertension,
Schlosser et al. compared a circulating miRNA profile previously related to pulmonary hyper-
tension in mice, rats and human plasma [20]. Similar to our study, they found large discrepan-
cies in expression levels between different experimental animal models and human pulmonary
hypertension, but also comparable relative rank orders of circulating miRNA levels across
Circulating microRNAs in rodent heart failure models
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these models. The latter suggests that in different species, circulating miRNAs may be regu-
lated in a similar, conserved way.
In S8 Table, we summarize the data on the investigated miRNAs in both in vitro or in vivo
rodent heart failure models and human heart failure studies. This table clearly demonstrates
the inconsistencies between tissue expression and circulating miRNA levels as well as differ-
ences between research groups. A probable cause for this discordancy and major restriction in
circulating miRNA research is the variation in methodology. A plethora of different protocols,
arrays and normalization methods is currently available, leading to varying and irreproducible
results among different studies. Of note, different sources of circulating miRNAs also contrib-
ute to inconsistent findings as it has been shown that expression patterns of miRNAs in whole
blood (containing cellular miRNAs) and miRNAs in cell-free plasma do not match in the same
individuals [21]. In the current study we used the same material and methods as in our previ-
ous study in human heart failure (with the exception of recommended protocol adjustments
and the use of primers suitable for rodents), therefore the lack of reproducibility in the 3 ani-
mal models caused by the methodology of choice is not probable.
The present findings may have implications for future circulating miRNA studies in heart
failure. Results obtained from animal studies cannot be directly translated to the human situation
and vice versa. Although the majority of circulating miRNA profiling studies are conducted in
human disease, in-depth miRNA studies investigating pathophysiological and molecular mecha-
nisms frequently focus on the tissue of interest using animal models. In our study we were able
to detect profound miRNA expression differences in the kidney and heart and although not sig-
nificant, potentially subtle expression differences in the heart of ischemic heart failure mice and
controls. However, the origin and function of circulating miRNAs are still elusive, therefore no
direct links can be made from miRNAs in the circulation and the function of the same miRNAs
in tissue. In heart failure it has been shown that the most abundant miRNAs in the circulation
do not reflect the miRNA signature in the myocardium itself [22]. In line with these results, we
found that miR-208a-3p and miR-499-5p -both cardiac specific and highly abundant in the
heart [23]- were either undetectable or very lowly expressed in the circulation of mice. This sug-
gests that the most differentially expressed circulating miRNAs do not originate from the myo-
cardium and are most likely derived from blood cells and the endothelium [2]. Although there
are examples of miRNA-loaded exosome trafficking from the heart to the circulation [24,25],
miRNAs in exosomes only represent a very small proportion of the whole miRNA pool in
plasma. Consequently, more research should be directed at increasing our understanding of the
biology behind the release and uptake of circulating miRNAs. Various experimental and animal
models could be useful for these studies, however circulating miRNA patterns found in human
disease should be validated in the animal model of choice to ensure comparability of the miRNA
response between species and the reliability of subsequent results.
There are limitations of this work. First, relatively small animal numbers were used in this
study. Second, because of the lack of a gold standard regarding the techniques of measuring
and normalization of circulating miRNAs, other methodologies may result in slightly different
findings. However, the presently reported consistent discordant findings between circulating
miRNA profiles in human heart failure and animal models of heart failure may be of great
importance for future translational circulating miRNA studies.
To conclude, in this study we were able to detect a set of miRNAs previously related to
heart failure in plasma of 3 animal models of heart failure. No circulating miRNA expression
differences between heart failure animals and matching controls could be observed as previ-
ously identified in human heart failure. This study provides valuable information underlining
the complex nature of circulating miRNAs and emphasizes on the challenges in the translation
of circulating miRNA profiles between species.
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